Finland Pharmaceutical Licensing

This record concerns retail pharmacy, medicinal product wholesale and industrial manufacturing of human medicines in Finland. All three activities are regulated centrally by Fimea; there is no US-style state／provincial licensing structure. The licence-holder structure differs for pharmacy, wholesale and manufacturing licences and should be matched to the actual business, premises, medicines, logistics and personnel on a case-by-case basis.

Official materials do not identify general company formation, minimum capital, a specific company form or foreign ownership percentage as uniform thresholds for the three licence types. A manufacturing licence application requires the company’s constitutional documents or equivalent; a foreign operator with a branch registered in Finland must submit a branch registration extract. This is an application-document requirement, not a complete determination of foreign-investment access or company formation approvals. A pharmacy licence, by contrast, is personal and cannot be presumed to be acquired through a company acquisition.

— Verify separately: company and tax registration, pharmacy licence, wholesale licence, manufacturing licence, personal qualifications, product marketing authorisation, import and controlled-drug licences.

— Excluded from scope: medical devices, veterinary medicines, case-specific rules for hospital pharmacies, and the new system for non-pharmacy retail sale of self-medication medicines, which takes effect only in 2027.

Fimea is the licensing and supervisory authority for pharmacies, medicinal product wholesale and industrial manufacturing. Its regulatory responsibilities include issuing licences, GMP／GDP inspections, and quality and traceability controls; details related to wholesale and manufacturing licences are entered into the relevant EMA databases. Finland’s central regulatory system should not be misrepresented as local-authority licensing.

The main legislation is the Medicines Act 395/1987 and the Medicines Decree 693/1987. EU Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) are implemented through Fimea’s licensing and inspections. Controlled drugs are additionally governed by the Narcotics Act framework, with Fimea as the licensing and supervisory authority.

— Fimea: business licences, inspections, certain product marketing authorisations and controlled-drug licences.

— Finlex／Ministry of Social Affairs and Health: current legislation, regulations and Fimea public-law fee orders.

— EMA／European Commission: participates in product marketing authorisation procedures; it does not replace Fimea’s business licences.

Operating a pharmacy business requires an apteekkilupa granted by Fimea. The authorisation applies to a specific pharmacy business in a designated municipality or part of a municipality. Fimea publishes notices inviting applications for new or vacant authorisations; applications must be submitted within 30 days of the notice, using the form confirmed by Fimea and either electronically or in writing. There is no application fee, but a fee is charged for the authorisation decision.

An authorisation may be granted only to an authorised proviisori. When assessing several eligible applicants, Fimea considers their experience in pharmacy or other pharmaceutical supply duties, relevant studies, management ability, and other activities. Medicines for the public may generally be supplied only through pharmacies, subsidiary pharmacies, pharmacy service points, or online pharmacy services. Traditional herbal products and homeopathic products, among others, are subject to statutory exceptions or product-specific limitations; they cannot all be treated as ordinary prescription medicines.

— A pharmacy authorisation is personal and may not be leased or transferred.

— Online pharmacy service: If a new operator intends to continue the outgoing operator’s online service, it should first notify Fimea; regulations allow the service to continue without interruption while the notification is being processed.

— Pharmacy service point: A new operator wishing to continue a service point must apply for a service-point authorisation; temporary continuity of operation during a handover does not mean that the authorisation transfers automatically.

Wholesale comprises the procurement or other acquisition, possession, sale or supply, and export of medicinal products, and does not include direct supply to the public. Wholesale may be conducted only under an authorisation from Fimea. Applicants must demonstrate that they have suitable premises, equipment, instruments and personnel. The application materials include information about the applicant and locations; a description of activities; a list of medicinal products intended for distribution; details of the premises; an organisation chart; information about the responsible person and deputy arrangements; and details of key outsourcing and contracts.

Wholesalers must comply with GDP. Their documented quality system must cover, at a minimum, staff competence, storage and transportation, supplier and customer qualification, traceability, deviations, changes, risks, returns, complaints, recalls, and oversight of outsourced activities. This system is an ongoing operational obligation and cannot be replaced by general logistics credentials.

— Submit the current application form to Fimea’s registry; Fimea may request additional information and may conduct a GDP inspection as part of the application process.

— Before applying, it is advisable to complete the company and location details in the EMA Organisation Management Service; this is Fimea’s guidance on preparing an application.

— The wholesale responsible person must be an authorised proviisori employed directly; this role should not be confused with the equivalent responsible-person role at a manufacturing plant or another wholesale business.

Industrial manufacture of medicinal products must be carried out by a manufacturing plant with acceptable manufacturing premises and equipment and an authorisation from Fimea. This authorisation covers full or partial manufacture, dividing, packaging and labelling. A separate manufacturing authorisation is also required to manufacture medicinal products with a marketing authorisation or to import investigational medicinal products from outside the European Economic Area. A manufacturing authorisation is not a product marketing authorisation.

Applications are submitted in free format to Fimea’s registry and must include the information required under section 1 of the Medicines Decree: details of the entity; the products, starting materials and dosage forms intended for manufacture; estimated production volumes; the site and premises and equipment; quality assurance; personnel; and details of the responsible person and qualified personnel. Compliance with GMP is a prerequisite for granting the authorisation; the authorisation is limited to the dosage forms or active substances specified in the document.

— Contract manufacturers and contract analytical laboratories conducting release testing of active substances or medicinal products must also obtain the relevant authorisation for the activities they perform.

— Investigational medicinal product manufacture and advanced therapy products are subject to separate provisions or rules; coverage cannot be presumed from an ordinary industrial manufacturing authorisation.

— Manufacturing plant authorisations, variations and GMP inspections are subject to fees; the applicable fees are those in force under the ministerial decree for the relevant year and as confirmed by Fimea.

An applicant for a pharmacy authorisation must be a proviisori authorised in Finland; as a rule, the licensed pharmacy operator must operate the pharmacy itself. A wholesaler must directly employ an authorised proviisori as the responsible person. These are distinct business roles and cannot be replaced solely by a general pharmacist, consultant or outsourced position.

The manufacturing plant’s responsible person must be directly employed and is responsible for product compliance, quality, and manufacturing and quality-control rules. The law requires this person to be an authorised proviisori or to hold a relevant higher-education qualification and have sufficient experience in manufacturing or quality assurance. Fimea also states that a pharmaceutical manufacturing plant must have a qualified QP. The specific appointee, allocation of duties and deputy arrangements should be assessed against the actual products and scope of the authorisation.

— Pharmacy: applicant must be an authorised proviisori and must personally hold the authorisation.

— Wholesale: directly employed responsible person, deputy arrangements, and the competence and resources required under GDP.

— Manufacturing: responsible person, QP, allocation of GMP duties, and quality release arrangements.

A pharmacy authorisation applies to the municipality or area designated by Fimea and to the statutory pharmacy channels. This review did not identify nationally uniform area, shelving or room-layout figures applicable to all ordinary pharmacies; accordingly, no area or pharmacist-coverage rule is invented. Establishment, relocation, service points and online services should be confirmed through Fimea’s case-specific authorisation or notification procedures.

Wholesale premises, equipment, information systems, storage and transport must support GDP; Fimea inspections assess temperature monitoring, data integrity, business continuity and supply-chain controls. Manufacturing requires acceptable manufacturing premises and equipment, with quality assurance and GMP covering manufacture, testing, release and storage.

— Pharmacy: the authorisation is limited to the designated business and area; no uniform area requirement has been derived from the official materials reviewed.

— Wholesale: establish GDP controls based on the actual warehousing, transport, information systems, outsourcing and product conditions.

— Manufacturing: configure facilities and equipment according to the site, dosage forms or starting materials, and quality activities specified in the authorisation; new construction or modifications may trigger a prior inspection.

For pharmacies, Fimea publishes notices for new or vacant authorisations. Applicants should submit an application electronically or in writing within 30 days of the notice, using the confirmed form. At the time of application, applicants should provide a CV or other documents demonstrating the experience required for the comparative assessment; applicants residing abroad must also provide evidence that they meet the statutory conditions for granting the authorisation. Fimea’s e-service allows logged-in users to apply for a pharmacy authorisation or submit a notice relinquishing one.

For wholesale, the application should be submitted together with its attachments approximately 4–6 months before the planned opening; Fimea may request additional documents and conduct a GDP inspection. For manufacturing, a free-form application and the supporting documents listed in the Medicines Decree must be submitted, and an acceptable GMP inspection must be passed. The three routes cannot be substituted for one another by a single general business application.

— Pharmacy: announcement, 30-day application window, individual qualifications and competitive overall assessment.

— Wholesale: entity/location, activities, products, premises, organisation, responsible person, deputy and outsourcing information.

— Manufacturing: entity, products/active substances/dosage forms, estimated output, facilities and equipment, quality assurance, personnel and responsible-person information.

— All routes: Fimea may request supplementary information; the need for on-site/remote inspections depends on the actual activities and risks.

Fimea recommends that wholesalers apply approximately 4–6 months before the planned start and must issue a decision within 90 days of receiving a complete wholesale permit application. The processing period for a new manufacturing permit is 90 days, excluding time spent on supplementary information or inspections; manufacturing permit amendments usually take 30 days, likewise excluding supplementary information or inspections. For special reasons, this may be extended to 90 days, with the applicant notified in advance. The pharmacy application window is 30 days after the announcement; the overall pharmacy decision period was not verified in this review.

Fimea’s ministerial decree on public-law fees for 2026 is 1344/2025, effective from 1/1/2026 to 31/12/2026, replacing the 2025 ministerial decree. Pharmacy licence decisions, manufacturing/wholesale licences, changes and related inspections are all subject to fees; this record does not reproduce specific euro amounts that were not verified from the 2026 schedule opened during the review. The official materials opened also did not provide a uniform renewal or expiry cycle for the three categories of business licence, so they cannot support claims of permanent validity or fixed renewal intervals.

— Wholesale: Fimea decision period of 90 days; submission 4–6 months in advance is recommended.

— Manufacturing: 90 days for a new permit; amendments usually take 30 days, in both cases excluding time for supplementary information/inspections.

— Pharmacy: submit within 30 days after the announcement; the permit decision is subject to a fee, with the amount to be confirmed under the decree in force for that year.

Wholesalers are subject to risk-based GDP inspections at least once every five years. Inspections may be on-site, remote or hybrid, and assess the quality system, the responsibilities and authority of responsible persons, staff training, storage and transport, supply-chain qualification, computerised systems, data integrity, deviations, CAPA, recalls, internal audits, security of supply and compliance relating to controlled drugs. After an inspection, an effective CAPA plan must be submitted within the specified period.

Once licensed, manufacturing sites enter Fimea’s periodic risk-based GMP inspection programme; frequency depends on the complexity of activities, the criticality of the medicines and the site’s previous quality performance. Significant changes to premises or manufacturing may also require an inspection. A pharmacy licence holder must operate the pharmacy personally; where they are legally unable to do so personally for a short or longer period, the statutory deputy and notification rules must be followed.

— Wholesale: maintain GDP continuously, directly employ the responsible person, and ensure traceability, temperature control and oversight of outsourcing.

— Manufacturing: maintain GMP, quality assurance, personnel qualifications and the relevant inspection status in EudraGMDP continuously.

— Pharmacy: personal responsibility for operation and the applicable procedures for service points, online services and deputies.

A pharmacy permit is personal in nature, and the law expressly prohibits its leasing or transfer. The previous operator must continue operating until the new operator, who has obtained a pharmacy permit, takes over, and must provide the new operator with the financial, contractual, personnel and obligations-related information necessary to prepare for operation. This handover rule supports business continuity but does not constitute automatic transfer of the permit. If the new operator continues an online service, advance notification is required; continuation of a service point requires an application for a service-point permit.

A manufacturer seeking to extend or change the scope of its permit must apply to Fimea in advance; significant changes to production or quality control must be notified without delay. A change of responsible person or QP must be notified 30 days before the change, or without delay in an emergency. For changes to a wholesale location, responsible person, activities or scope, Fimea’s permit page states that a permit amendment is processed; the text opened for this review does not itemise which circumstances require notification, an amendment application or a new application. Obtain written confirmation from Fimea on the classification before implementation.

— Pharmacy: personal permit cannot be leased/transferred; handover must be to a new operator who has obtained a permit.

— Manufacturing: additions to dosage forms or active substances require a separate application; significant production/quality control changes must be notified.

— Wholesale: for any proposed transaction/change that may affect the approved entity, location, activities, products, responsible person or quality system, it is advisable to confirm the permit amendment route with Fimea before it takes effect.

— Share transaction: no official sources opened support the claim that any of the three types of licence automatically continue or transfer as a result of a share or asset transaction.

Before a medicine is sold to consumers in Finland, it must have a product-level marketing authorisation. Fimea explains that product authorisations may be obtained through Finland’s national procedure, the multi-country mutual recognition or decentralised procedure, or the centralised procedure, under which the European Commission grants an authorisation on the recommendation of the EMA. Applicants must demonstrate a favourable benefit-risk balance, quality, safety and efficacy. A product marketing authorisation is separate from pharmacy, wholesale or manufacturing operating permits and cannot replace them.

Section 17 of the Medicines Act distinguishes import rights by entity and source location: authorised industrial manufacturers, wholesale permit holders and statutory pharmacies, among others, may import within their respective statutory scopes. However, to import medicines authorised or registered for marketing from outside the European Economic Area, the importer must hold an industrial manufacturing permit and ensure that quality control is performed as required by the marketing authorisation. The manufacture, handling, import and export of controlled drugs are separately licensed by Fimea under the Narcotics Act.

— Products: check the marketing authorisation/registration/statutory exemption and actual sales status in Finland for each SKU.

— Imports: specifically check non-EEA sources, the importing entity, manufacturing permit, quality control and rules for investigational medicinal products.

— Controlled drugs: Fimea import, export, manufacturing and handling permits are additional and separate; ordinary pharmacy, wholesale or manufacturing permits do not automatically cover them.

— Traditional herbal medicines, homeopathic medicines, veterinary medicines, active substances and non-pharmacy retail of non-prescription medicines have boundary issues that should be checked separately according to product category and effective date.